Prostate Cancer

News and new technology innovations concerning how imaging technology can help diagnose and treat prostate cancer can be found on this channel.

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
Study Shows Sharp Decline in Cancer Screenings During First COVID-19 Surge
January 15, 2021 — In one of the first studies to examine the impact of the COVID-19 pandemic on cancer diagnoses,...
read more
The "US Prostate Cancer Nuclear Medicine Diagnostics Market to 2027 - Country Analysis and Forecast by Type; PET Product" report has been added to ResearchAndMarkets.com's offering. The prostate cancer nuclear medicine diagnostics market in the US was valued at $194.47M in 2019 and is expected to grow at a CAGR of 10.6% from 2020 to 2027 to reach $431.76M by 2027.

Getty Images

News | Prostate Cancer | January 13, 2021
US Prostate Cancer Nuclear Medicine Diagnostics Market Outlook
January 13, 2021 — The "US Prostate Cancer Nuclear Medicine Diagnostics Market to 2027 - Country Analysis and Forecast...
read more
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

News | Prostate Cancer | January 11, 2021
MRI Frequently Underestimates Tumor Size in Prostate Cancer
January 11, 2021 — A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic...
read more
For men with early-stage prostate cancer, choices about initial treatment carry varying risks of "financial toxicity," reports a study in The Journal of Urology, Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Getty Images

News | Prostate Cancer | December 02, 2020
Radiation Therapy Has the Greatest Impact on Patient Finances
December 2, 2020 — For men with early-stage prostate cancer, choices about initial treatment carry varying risks of "...
read more
 Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that their manufacturing partner Nucleis (Liege, Belgium) has manufactured and shipped their first patient doses of rhPSMA-7.3 (18F), an investigational Prostate-Specific Membrane Antigen (PSMA)-targeted radiohybrid PET imaging agent, currently under evaluation in clinical trials in men with newly diagnosed prostate cancer and suspected prostate cancer recurrence.
News | PET Imaging | November 25, 2020
Blue Earth Diagnostics Announces First Patient Doses of PET Imaging Agent in Collaboration with Nucleis Radiopharmaceuticals
November 25, 2020 — Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that their...
read more
 MIM Software Inc. announced a collaboration with Peter MacCallum Cancer Centre (Peter Mac) in support of its Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) program.
News | Prostate Cancer | November 19, 2020
MIM Software Inc. Announces Collaboration with Peter MacCallum Cancer Centre to Improve Patient Management
November 19, 2020 — MIM Software Inc. announced a collaboration with Peter MacCallum Cancer Centre (Peter Mac) in...
read more
During active surveillance, prostate cancer is carefully monitored for signs of progression through regular prostate-specific antigen (PSA) screening, prostate exams, imaging, and repeat biopsies.

Getty Images

News | Prostate Cancer | November 18, 2020
Men with Negative Biopsies During Active Surveillance Have Good Outcomes
November 18, 2020 — Can early-stage prostate cancer "vanish" during follow-up? More likely the cancer is just "hidden...
read more
Penn study supports the use of more testicular shielding for men and children during diagnostics

Getty Images

News | Radiology Imaging | November 16, 2020
Diagnostic Imaging May Increase Risk of Testicular Cancer
November 16, 2020 — Early and repeated exposures to diagnostic imaging, such as X-rays and computed tomography (CT)...
read more
Minimizing delays to treatment could improve cancer survival rates, say researchers

Getty Images

News | Radiation Oncology | November 10, 2020
Every Month Delayed in Cancer Treatment Can Raise Risk of Death by Around 10%
November 10, 2020 — People whose treatment for cancer is delayed by even one month have in many cases a 6 to 13% higher...
read more
In this retrospective cohort study of men with low-risk prostate cancer followed up for a median of 7.6 years, African American men, compared with non-Hispanic White men, had a statistically significant increased 10-year cumulative incidence of disease progression and definitive treatment, but not metastasis or prostate cancer–specific mortality

Getty Images

News | Prostate Cancer | November 04, 2020
Active Surveillance Safe for African Americans with Low-risk Prostate Cancer
November 4, 2020 — Previous studies have shown that African American men are 2.4 times as likely to die from prostate...
read more
Metastasis-free survival is a strong surrogate endpoint for overall survival over biochemical failure for men receiving salvage radiotherapy for recurrent prostate cancer

Getty Images

News | Prostate Cancer | November 02, 2020
MFS Is a Strong Surrogate Endpoint for OS for Men Receiving Salvage RT
November 2, 2020 — An analysis of the phase III NRG Oncology clinical trial RTOG 9601 on men receiving salvage...
read more
Conceptual diagram of bio-organizational crushing technology based on high-intensity concentric ultrasonography. Image courtesy of Korea Institue of Science and Technology(KIST)

Conceptual diagram of bio-organizational crushing technology based on high-intensity concentric ultrasonography. Image courtesy of Korea Institue of Science and Technology(KIST)

News | Ultrasound Imaging | November 02, 2020
Destroying Cancer Cells with Non-surgical Ultrasound Treatment
November 2, 2020 — Focusing ultrasound energy on a target site in the body to generate heat can burn and destroy the...
read more
Follow up results on first multicenter trial to report outcomes of salvage low dose radiotherapy brachytherapy after external beam radiotherapy for prostate cancer
News | Prostate Cancer | October 30, 2020
Outcomes of Salvage Low Dose RT Brachytherapy After EBRT for Prostate Cancer
October 30, 2020 — Researchers involved in the phase II NRG Oncology RTOG 0526 trial studying low dose rate (LDR)...
read more
"Initial report of a randomized trial comparing conventional- vs conventional plus fluciclovine (18F) PET/CT imaging-guided post-prostatectomy radiotherapy for prostate cancer" was presented by Ashesh Jani, M.D., Winship Cancer Institute of Emory University, at ASTRO20
News | PET Imaging | October 26, 2020
Adding Advanced PET Scans to Radiation Treatment Plans for Prostate Cancer Increases Failure-free Survival Rates
October 26, 2020 — Adding the advanced PET radiotracer fluciclovine to conventional imaging to help guide radiation...
read more
A study from Winship Cancer Institute of Emory University (Winship) has the potential to change how patients whose prostate cancer recurs after prostatectomy are treated. The study will be featured in both the plenary session and press program of the American Society for Radiation Oncology (ASTRO) Annual Meeting on Monday, October 26.
News | Prostate Cancer | October 24, 2020
ASTRO Highlights Winship Study Showing Increased Failure-free Survival in Prostate Cancer
October 24, 2020 — A study from Winship Cancer Institute of Emory University (Winship) has the potential to change how...
read more
The FDA clearance, Quantib’s 6th to date, marks the first time a comprehensive AI prostate solution will be available to radiologists in the United States
News | Prostate Cancer | October 21, 2020
Quantib Receives FDA Clearance for First-to-Market Prostate Solution
October 21, 2020 — Quantib, a market leader in artificial intelligence solutions for radiology, today announced that it...
read more
Ezra, a NY-based startup transforming early cancer screening using magnetic resonance imaging (MRI), announced that it has received FDA 510(k) premarket authorization for its Artificial Intelligence, designed to decrease the cost of MRI-based cancer screening, assisting radiologists in their analysis of prostate MRI scans. It is the first prostate AI to be cleared by the FDA.
News | Artificial Intelligence | October 20, 2020
Ezra Receives FDA Clearance For Prostate Cancer Artificial Intelligence
October 20, 2020 — Ezra, a NY-based startup transforming early cancer screening using magnetic resonance imaging (MRI...
read more
ASTRO urges radiation oncology benefits management company eviCore to reconsider a move that requires shorter treatment regimens without regard for physician judgement

Getty Images

News | Radiation Oncology | October 02, 2020
Benefits Manager Policy Disrupts Patient-physician Decision Making for Breast and Prostate Cancer Radiation Treatments
October 2, 2020 — Radiation oncologists expressed serious concerns about a new private insurance coverage policy that...
read more
High-intensity focused ultrasound (HIFU), a technology used to treat localized prostate cancer, has shown adequate control of prostate cancer while avoiding major side effects of surgery or radiation therapy, according to a new study in The Journal of Urology, Official Journal of the American Urological Association

Getty Images

News | Prostate Cancer | September 08, 2020
First U.S. Study Shows Promising Outcomes for High-intensity Focused Ultrasound for Prostate Cancer
September 8, 2020 — Approved by the US Food and Drug Administration (FDA) in 2015 for prostate tissue ablation, the...
read more
Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

News | Prostate Cancer | July 28, 2020
Artificial Intelligence Identifies Prostate Cancer with Near-perfect Accuracy
July 28, 2020 — A study published in The Lancet Digital Health by UPMC and University of Pittsburgh researchers...
read more
© Copyright Wainscot Media. All Rights Reserved.